Austrian Hospital Uses CBD to Treat Patients With COVID-19

An Austrian hospital started using CBD to treat patients with COVID-19, news portal Heute reported on 31st of January 2021.

The doctors in Klagenfurt hospital increased the CBD dosage for COVID-19 to up to 300mg in the treatment period of three weeks.

“We have seen that the inflammation parameters in the blood go down, and people leave the hospital faster than the comparison group. CBD supports the immune system,” said Rudolf Likar, Head of Intensive Care at Klagenfurt Clinic, for Radio Kärnten.

From now on, CBD will probably be used routinely in this hospital.

Heute reports that Israel is also working on officially approving CBD for COVID-19 therapy. In April last year, Israeli scientists announced several research projects involving CBD usage in COVID-19 patients.

We can expect more hospitals to use CBD to treat patients with COVID-19. Previously, animal model studies have shown CBD reduces cytokine storm, the leading cause of mortality in COVID-19 patients.  

Cytokine storm is a reaction of the organism that leads to inflammatory processes in the lungs and blockage of blood vessels, and organ failure. The most dangerous thing is that this reaction takes place quickly, within 24 to 48 hours, so doctors in such a case are almost powerless to fight for the patient’s life.

The cytokine storm causes acute respiratory distress syndrome (ARDS), the reason why patients end up on a respirator. According to scientific data, as many as 30-50% of patients who end up on a respirator expect a fatal outcome.

Several scientific studies have shown that CBD can block interleukin-6 (IL-6), an inflammatory molecule that in some cases causes a whole cascade of destructive cytokine storms when infected with a new coronavirus.

According to the latest research published in January 2022, cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA) could be effective in preventing and treating COVID-19. Theoretically, the best way to consume these compounds would be an oral intake of a full-spectrum product.


In addition to promoting public knowledge about CBD and other cannabinoids, at Ilesol Pharmaceuticals, we strongly believe in the importance of providing scientific evidence prior to claiming any possible health benefits, and we, therefore, do not advise our customers or readers of our blog to use any product in the treatment of any illness before it has been approved by the international drug regulatory agencies.

Reviewed by Sasha Bajilo, founder of ILESOL Pharmaceuticals, an industrial scale producer of CBD products and formulations. Expert on Hemp/Cannabis policy, member of the Croatian Ministry of Health regulatory commission for medical cannabis.